Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Döhner · SciRah

Researcher profile · Semantic Scholar

H. Döhner

Share profile

H. Döhner — researcher profile on SciRah

h-index: 150
Works: 1,490
Citations: 108K

Most-cited papers

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
H. Döhner, C. Dinardo, Andrew H. Wei, B. Lowenberg +19 more
2024Blood255 citations Open access
Semantic Scholar
Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
K. Pratz, B. Jonas, V. Pullarkat, M. Thirman +23 more
2024American journal of hematology/oncology227 citations Open access
Semantic Scholar
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
H. Döhner, K. Pratz, C. Dinardo, Andrew H. Wei +14 more
2024Blood152 citations Open access
Semantic Scholar
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Martha L. Arellano, M. Thirman, J. Dipersio, M. Heiblig +32 more
2025Blood85 citations Open access
Semantic Scholar
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Naval G. Daver, Paresh Vyas, G. Huls, H. Döhner +18 more
2025Blood76 citations Open access
Semantic Scholar
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
H. Döhner, D. Weber, J. Krzykalla, W. Fiedler +33 more
2023The Lancet Haematology55 citations
Semantic Scholar
Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
M. Voso, L. Guarnera, Soren Lehmann, K. Döhner +16 more
2024Blood52 citations
Semantic Scholar
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
F. Ravandi, M. Subklewe, R. Walter, P. Vachhani +15 more
2024Leukemia and Lymphoma35 citations Open access
Semantic Scholar
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study
Alberto Hernández-Sánchez, T. González, M. Sobas, E. Sträng +26 more
2024Leukemia35 citations Open access
Semantic Scholar
The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities
Evelyn Ramberger, Valeriia Sapozhnikova, Yuen Lam Dora Ng, A. Dolnik +31 more
2024Nature Cancer35 citations Open access
Semantic Scholar
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML
P. Montesinos, Dylan M. Marchione, Christian Récher, M. Heuser +15 more
2025Blood Advances33 citations Open access
Semantic Scholar
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
U. Platzbecker, Lionel Adès, P. Montesinos, E. Ammatuna +45 more
2025Journal of Clinical Oncology27 citations Open access
Semantic Scholar
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
Adriane Halik, Marlon Tilgner, Patricia Silva, Natalia Estrada +28 more
2024Journal of Hematology & Oncology26 citations Open access
Semantic Scholar
Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
S. Cocciardi, Maral Saadati, Nina Weiß, D. Späth +18 more
2025HemaSphere25 citations Open access
Semantic Scholar
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
C. Récher, J. O'Nions, I. Aldoss, A. Piérola +52 more
2024Blood25 citations Open access
Semantic Scholar
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
Frank G. Rücker, Lars Bullinger, S. Cocciardi, Sabrina Skambraks +27 more
2024Blood Advances23 citations Open access
Semantic Scholar
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
M. Sobas, A. Turki, Angela Villaverde Ramiro, Alberto Hernández-Sánchez +31 more
2024Haematologica22 citations Open access
Semantic Scholar
Bleximenib in combination with intensive chemotherapy: A phase 1b study in newly diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 alterations
H. Döhner, Andre C. Schuh, Christian Récher, J. O'Nions +47 more
2025Blood17 citations
Semantic Scholar
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
G. Roboz, Guillermo F. Sanz, Elizabeth A. Griffiths, Karen W. L. Yee +17 more
2024Blood Advances13 citations Open access
Semantic Scholar
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
Marius Bill, J. Eckardt, K. Döhner, Maximillian-Alexander Röhnert +53 more
2025Leukemia12 citations Open access
Semantic Scholar
Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia – a HARMONY study
Alberto Hernández-Sánchez, Ángela Villaverde Ramiro, E. Sträng, A. Turki +29 more
2026Leukemia11 citations Open access
Semantic Scholar
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
Richard M. Stone, Jun Yin, S. Mandrekar, A. Benner +27 more
2024Blood11 citations Open access
Semantic Scholar
Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia
R. Mecklenbrauck, Nora M. Borchert, R. Gabdoulline, Piroska Poll +20 more
2025Leukemia10 citations Open access
Semantic Scholar
Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States
C. Lachowiez, Georgios Asimomitis, Elsa Bernard, S. Devlin +28 more
2025Blood Cancer Discovery9 citations
Semantic Scholar
Development of a 29‐Color Single‐Tube Full Spectrum Flow Cytometry Assay for the Detection of Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Zhong Zhang, Miriam Wilhelm, Ines Sieber, H. Döhner +1 more
2025Cytometry Part A9 citations Open access
Semantic Scholar
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
R. Schlenk, D. Weber, J. Krzykalla, T. Kindler +17 more
2023Scientific Reports9 citations Open access
Semantic Scholar
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
C. Rautenberg, J. Middeke, C. Röllig, Matthias Stelljes +43 more
2025Blood Cancer Journal8 citations Open access
Semantic Scholar
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
V. Pullarkat, K. Pratz, H. Döhner, Christian Récher +16 more
2025Blood Cancer Journal8 citations Open access
Semantic Scholar
Neurological complications of the central nervous system after allogeneic stem cell transplantation: the role of TA-TMA as a potential underreported cause.
E. Sala, A. Neagoie, Jan Lewerenz, Maral Saadati +5 more
2024Transplantation and Cellular Therapy8 citations Open access
Semantic Scholar
Phase 1b study of bleximenib in combination with venetoclax in Acute Myeloid Leukemia with KMT2A or NPM1 alterations
J. O'Nions, Andrew Wei, Jordi Esteve, I. Aldoss +45 more
2025Blood7 citations
Semantic Scholar
Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population.
V. Wais, A. Gantner, K. Strauss, A. Neagoie +5 more
2024Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis7 citations Open access
Semantic Scholar
Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients
V. Gaidzik, Regine Mayer-Steinacker, M. Wittau, Markus Schultheiss +14 more
2024Sarcoma7 citations Open access
Semantic Scholar
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All‐Trans Retinoic Acid or Valproic Acid to Decitabine
H. Bresser, C. Schmoor, O. Grishina, Dietmar Pfeifer +30 more
2024European Journal of Haematology7 citations Open access
Semantic Scholar
Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q
Etienne Sollier, Anna Riedel, U. Toprak, J. Wierzbinska +53 more
2025Blood Cancer Discovery6 citations Open access
Semantic Scholar
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL
Alena Sophie Ehrmann, M. Quijada-Álamo, Viola Close, Min Guo +17 more
2025Leukemia6 citations Open access
Semantic Scholar
A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRDneg remission after intensive induction
K. Döhner, H. Döhner, D. Späth, S. Kapp-Schwoerer +16 more
2025HemaSphere5 citations Open access
Semantic Scholar
Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials
J. Tettero, Sträng Eric, Sylvie D. Freeman, Richard Dillon +27 more
2025Blood5 citations
Semantic Scholar
Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
Frank G. Rücker, A. Corbacioglu, J. Krzykalla, S. Cocciardi +22 more
2024HemaSphere5 citations Open access
Semantic Scholar
The Genomic Landscape and Its Clinical Implication in NPM1-Mutated AML Patients: A Study within the AMLSG 09-09 Clinical Trial
S. Cocciardi, Nina Weiß, Maral Saadati, Sabrina Skambraks +20 more
2023Blood5 citations
Semantic Scholar
A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL
Min Guo, Tugba Memis, Alena Sophie Ehrmann, A. Pittrof +11 more
2025Blood4 citations Open access
Semantic Scholar
AML-418: Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax+Azacitidine (VEN+AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations
Andrew H. Wei, Jordi Esteve Reyner, S. Garciaz, I. Aldoss +48 more
2025Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation
E. Stein, C. Dinardo, Amir T. Fathi, Alice S. Mims +19 more
2025Blood4 citations
Semantic Scholar
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia
H. Döhner, D. Späth, Maral Saadati, Walter Fiedler +28 more
2026Blood3 citations Open access
Semantic Scholar
A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1 -mutated or KMT2A -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).
G. Huls, Michael W. M. Kühn, P. Vyas, H. Döhner +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia
R. Mecklenbrauck, Ángela Villaverde Ramiro, E. Sträng, R. Gabdoulline +26 more
2026Leukemia3 citations Open access
Semantic Scholar
Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)
H. Döhner, G. Huls, Paresh Vyas
2025Blood3 citations
Semantic Scholar
Clinical Evaluation of Complete Remission (CR) with Partial Hematologic Recovery (CRh) in Acute Myeloid Leukemia: A Report of 7,235 Patients from Seven Cohorts
Jacob S. Appelbaum, Andrew H. Wei, S. Mandrekar, I. Tiong +25 more
2024Leukemia3 citations
Semantic Scholar
S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
Frank G. Rücker, L. Bullinger, S. Cocciardi, Sabrina Skambraks +24 more
2023HemaSphere3 citations Open access
Semantic Scholar
Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations
H. Döhner, Andre C. Schuh, C. Recher, Jenny O'Nions +47 more
2026Transplantation and Cellular Therapy2 citations
Semantic Scholar
Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML
Samantha Nier, Jana Pelouchova, Ralph Hills, S. Salek +8 more
2025Future Oncology2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Döhner×24
Invite
K. Döhner — researcher profile on SciRah
C. Röllig×11
Invite
C. Röllig — researcher profile on SciRah
M. Heuser×11
Invite
M. Heuser — researcher profile on SciRah
M. Lübbert×10
Invite
M. Lübbert — researcher profile on SciRah

×10

Invite

V. Gaidzik — researcher profile on SciRah

Invite

F. Thol — researcher profile on SciRah

U. Platzbecker×9

Invite

U. Platzbecker — researcher profile on SciRah

Lars Bullinger×9

Invite

Lars Bullinger — researcher profile on SciRah

Invite

A. Benner — researcher profile on SciRah

Invite

K. Metzeler — researcher profile on SciRah

Invite

C. Thiede — researcher profile on SciRah

Invite

A. Ganser — researcher profile on SciRah